Pharvaris Highlights Oral HAE Treatment Strategy at Morgan Stanley
Pharvaris CEO Berndt A. Modig and Head of Investor Relations Maggie Beller presented at Morgan Stanley’s 24th Annual Global Healthcare Conference on September 15, 2026. Modig reviewed Pharvaris’ 23-year history in hereditary angioedema (HAE) treatment development and its focus on creating oral therapies.
Modig previously worked with Jochen Knolle, an inventor of icatibant, before Shire acquired the related business in 2008. Icatibant remains a widely used subcutaneous treatment for acute HAE attacks. Pharvaris was founded around the goal of addressing patient demand for more convenient oral alternatives.
The transcript excerpt does not provide new clinical data, regulatory decisions, revenue guidance or specific development milestones. For traders, the key themes are Pharvaris’ oral HAE strategy, competition in rare-disease medicine and the company’s long-term product-development narrative. The excerpt concerns a biotechnology company and does not directly involve cryptocurrency markets.
Neutral
The expected cryptocurrency-market impact is neutral because the article concerns Pharvaris, a biotechnology company developing oral treatments for hereditary angioedema, and contains no cryptocurrency, blockchain or digital-asset information. It also provides no new clinical results, regulatory approval or financial guidance that would materially affect broader risk sentiment.
In the short term, crypto traders should not expect a direct effect on Bitcoin, Ethereum or other digital assets. Any market reaction would likely be limited to Pharvaris’ biotech-related equity and could depend on later disclosures, such as clinical-trial data, regulatory progress or commercial updates. In past cases, healthcare conference presentations without new quantitative data have generally produced limited cross-market impact.
Longer term, successful oral HAE development could support Pharvaris’ valuation and investor confidence in the rare-disease sector. However, that outcome would not normally translate into a sustained crypto-market trend unless it coincided with broader changes in risk appetite, interest rates or institutional capital flows. Traders should therefore treat this transcript as sector-specific biotechnology news rather than a cryptocurrency catalyst.